A2 Biotherapeutics Secures $80 Million Series C Funding to Advance CAR-T Cell Therapies
A2 Biotherapeutics, a California-based biotechnology company focused on developing next-generation CAR-T cell therapies, has raised $80 million in its Series C funding round. The investment aims to accelerate the company’s clinical programs and expand its innovative cell therapy pipeline.
The funding round was led by existing investors including The Column Group, Vida Ventures, and Samsara BioCapital, with participation from new investors such as Perceptive Advisors and Aisling Capital. The strong backing from leading life sciences investors reflects confidence in A2 Biotherapeutics’ approach to addressing solid tumors through precision cell therapies.
A2 Biotherapeutics is pioneering the use of Tmod™ platform technology, which enhances CAR-T therapies by enabling them to selectively target tumor cells while sparing healthy tissues. This novel approach aims to overcome the limitations of current CAR-T therapies, particularly in treating solid tumors.
The newly secured funds will support the advancement of A2 Biotherapeutics’ lead candidates through clinical trials, as well as the development of additional programs in its pipeline. The company plans to expand its manufacturing capabilities and strengthen its research and development teams to accelerate its mission.
CEO Scott Foraker expressed gratitude for the continued support from investors and highlighted the importance of this funding in bringing transformative cancer therapies to patients. He emphasized that A2 Biotherapeutics’ platform has the potential to revolutionize cancer treatment by providing safer and more effective therapies.
The Series C funding comes at a critical time as the field of CAR-T therapy continues to evolve, with increasing efforts to tackle the challenges posed by solid tumors. A2 Biotherapeutics’ unique approach has garnered attention within the biotech community for its potential to significantly improve patient outcomes.
Investors have praised the company’s scientific rigor and promising clinical data, with Perceptive Advisors noting that A2 Biotherapeutics is well-positioned to make meaningful contributions to the field of immuno-oncology.
As A2 Biotherapeutics moves forward with its clinical programs, the company remains committed to its mission of delivering cutting-edge therapies that offer new hope to cancer patients worldwide.
